









Markets
/
Stocks
/
nasdaq-sabs
/

SAB Biotherapeutics Inc

SABS

2.470USD

-0.320-11.47%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

22.95MMarket Cap

LossP/E TTM



SAB Biotherapeutics Inc

2.470

-0.320-11.47%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

150 / 506

Overall Ranking

259 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Buy

Current Rating

8.833

Target Price

+216.61%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing fully human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company's lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine, the only transgenic animal with a human artificial chromosome, its DiversitAb drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, fully-human IgGs that can address a wide range of serious unmet needs in human diseases. The Company's SAB-176 pipeline program is a multivalent, broadly neutralizing -human polyclonal IgG therapeutic candidate in development for the treatment or prevention of severe influenza.

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.32M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 81.98.

Fairly Valued

The company’s latest PE is -0.62, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 3.86M shares, decreasing 28.43% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 282.37K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.75.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.23, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 37.88%.

Score

Industry at a Glance

Previous score

6.23

Change



Financials

6.76

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.28

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.67

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.41

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -0.70, which is -26.89% below the recent high of -0.51 and -78.12% above the recent low of -1.24.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 150/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.40, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for SAB Biotherapeutics Inc is 8.00, with a high of 14.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

8.40

Change

Support & Resistance

No Data

Analyst Rating

Based on 6 analysts

Buy

Current Rating

8.833

Target Price

+216.61%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

SAB Biotherapeutics Inc

SABS

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 8.26, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 3.15 and the support level at 2.21, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.26

Change

-1.76

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.108

Buy

RSI(14)

57.527

Neutral

STOCH(KDJ)(9,3,3)

60.611

Neutral

ATR(14)

0.198

High Vlolatility

CCI(14)

140.845

Buy

Williams %R

51.685

Neutral

TRIX(12,20)

0.235

Sell

StochRSI(14)

43.837

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

2.418

Buy

MA10

2.269

Buy

MA20

2.227

Buy

MA50

2.298

Buy

MA100

2.068

Buy

MA200

2.249

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 41.43%, representing a quarter-over-quarter decrease of 12.91%. The largest institutional shareholder is The Vanguard, holding a total of 282.37K shares, representing 2.71% of shares outstanding, with 9.76% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BVF Partners L.P.

917.83K

Sullivan (Eddie Joe)

523.23K

Hamilton (Christine E)

501.81K

+0.50%

Sessa Capital

458.46K

Hamilton (Edward D.)

308.32K

The Vanguard Group, Inc.

Star Investors

277.51K

+0.05%

Geode Capital Management, L.L.C.

84.69K

+5.55%

Big Cypress Holdings, L.L.C.

54.77K

Pathstone

50.65K

Spragens (Jeffrey G.)

39.50K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.05, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.58. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.